Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model

Journal of Endocrinology

Volumn 211, Issue 3, 2011, Pages 297-304

  Gray, Ashley ^a   Aronson, William J ^a,b   Barnard, R James ^a   Mehta, Hemal ^b   Wan, Junxiang ^b   Said, Jonathan ^b   Cohen, Pinchas ^b   Galet, Colette ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS ANTIGEN; CYCLINE; GLUCOSE; INSULIN; KI 67 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BODY COMPOSITION; BODY WEIGHT; C57BL 6 MOUSE; CANCER INCIDENCE; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; CROSS BREEDING; DIET RESTRICTION; GENE DELETION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DIET; TRANSGENIC MOUSE; WEANING; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA PRIMERS; FASTING; GENE DELETION; GENES, MYC; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 83455224836     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0240     Document Type: Article

References (51)

1. Baxter RC 1994 Insulin-like growth factor binding proteins in the human circulation: a review. Hormone Research 42 140-144.
2. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566.
3. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP et al. 2001 Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiology, Biomarkers and Prevention 10 421-427.
4. Cohen P, Peehl DM, Lamson G & Rosenfeld RG 1991 Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. Journal of Clinical Endocrinology and Metabolism 73 401-407.
5. Cohen P, Peehl DM & Rosenfeld RG 1994 The IGF axis in the prostate. Hormone and Metabolic Research 26 81-84.
6. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M & Carroll PR 2009 The impact of obesity on overall and cancer specific survival in men with prostate cancer. Journal of Urology 182 112-117.
7. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV & Sawyers CL 2003 Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 223-238.
8. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P & Weinzimer SA 1999 Cellular actions of insulin-like growth factor binding proteins. Hormone and Metabolic Research 31 192-202.
9. Firth SM 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 23 824-854.
10. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ & Kolonel LN 2010 Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort. Prostate 70 906-915.
11. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ & Willett WC 2003 Body mass index and risk of prostate cancer in U.S. health professionals. Journal of National Cancer Institute 95 1240-1244.
12. Hammarsten J, Damber JE, Peeker R, Mellstrom D & Hogstedt B 2010 A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiology 34 574-579.
13. Harman SM, Metter EJ, Blackman MR, Landis PK & Carter HB 2000 Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. Journal of Clinical Endocrinology and Metabolism 85 4258-4265.
14. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB & Platz EA 2004 Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 63 253-258.
15. Janssen JA, Stolk RP, Pols HA, Grobbee DE & Lamberts SW 1998 Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arteriosclerosis, Thrombosis, and Vascular Biology 18 277-282.
16. Johansson M, McKay JD, Rinaldi S, Wiklund F, Adami H-O, Grönberg H, Kaaks R & Stattin P 2009 Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate 69 1281-1291.
17. Jones JI & Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 16 3-34.
18. Kadowaki T & Yamauchi T 2005 Adiponectin and adiponectin receptors. Endocrine Reviews 26 439-451.
19. Katz LE, Satin-Smith MS, Collett-Solberg P, Baker L, Stanley CA & Cohen P 1998 Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting. Journal of Clinical Endocrinology and Metabolism 83 4426-4430.
20. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J et al. 2006 Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clinical Cancer Research 12 4662-4670.
21. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P et al. 2008 Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Research 68 3066-3073.
22. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA & Edwards BK 2011 Annual Report to the Nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. Journal of National Cancer Institute 103 714-736.
23. Lehrer S, Diamond EJ, Stagger S, Stone NN & Stock RG 2002 Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 50 1-3.
24. Lemne C & Brismar K 1998 Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome -a study in borderline hypertension. Blood Pressure 7 89-95.
25. Leu JI, Crissey MA, Craig LE & Taub R 2003 Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP beta and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation. Molecular and Cellular Biology 23 1251-1259.
26. Leu JL & George DL 2007 Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes and Development 21 3095-3109.
27. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D & Adami HO 1997 Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer 76 1115-1118.
28. Meinbach D & Lokeshwar B 2006 Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Urologic Oncology 24 294-306
29. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P & Aronson WJ 2002 Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes and Control 13 929-935.
30. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D & Aronson WJ 2003a Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clinical Cancer Research 9 2734-2743.
31. Ngo TH, Barnard RJ, Leung PS, Cohen P & Aronson WJ 2003b Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144 2319-2324.
32. Oh Y, Muller HL, Lee DY, Fielder PJ & Rosenfeld RG 1993 Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 132 1337-1344.
33. Reaven GM 1998 Insulin resistance and human disease: a short history. Journal of Basic and Clinical Physiology and Pharmacology 9 387-406.
34. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A & Thun MJ 2001 Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiology, Biomarkers and Prevention 10 345-353.
35. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ & Calle EE 2007 Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers & Prevention 16 63-69.
36. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM &Martin RM 2009 Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. International Journal of Cancer 124 2416-2429.
37. Shariat SF, Bergamaschi F, Adler HL, Nguyen C, KattanMW, Wheeler TM& Slawin KM 2000 Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology 56 423-429.
38. Signorello LB, Brismar K, Bergstrom R, Andersson SO, Wolk A, Trichopoulos D & Adami HO 1999 Insulin-like growth factor-binding protein-1 and prostate cancer. Journal of National Cancer Institute 91 1965-1967.
39. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G & Kaaks R 2000 Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. Journal of National Cancer Institute 92 1910-1917.
40. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A & Olsson T 2001 Leptin is associated with increased prostate cancer risk: a nested case-referent study. Journal of Clinical Endocrinology and Metabolism 86 1341-1345.
41. Taicher GZ, Tinsley FC, Reiderman A & Heiman ML 2003 Quantitative magnetic resonance (QMR) method for bone and whole-body-composition analysis. Analytical and Bioanalytical Chemistry 377 990-1002.
42. Tripathi G, Salih DA, Drozd AC, Cosgrove RA, Cobb LJ & Pell JM 2009 IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo. The FASEB Journal 23 2616-2626.
43. Wallstrom P, Bjartell A, Gullberg B, Olsson H &Wirfalt E 2009 A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. British Journal of Cancer 100 1799-1805.
44. Watson CS, Bialek P, Anzo M, Khosravi J, Yee SP & Han VK 2006 Elevated circulating insulin-like growth factor binding protein-1 is sufficient to cause fetal growth restriction. Endocrinology 147 1175-1186.
45. Wheatcroft SB & Kearney MT 2009 IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends in Endocrinology and Metabolism 20 153-162.
46. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO & Trichopoulos D 1998 Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. Journal of National Cancer Institute 90 911-915.
47. Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D et al. 2006 The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. Journal of Endocrinology 189 289-299.
48. Yki-Jarvinen H, Makimattila S, Utriainen T & Rutanen EM 1995 Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. Journal of Clinical Endocrinology and Metabolism 80 3227-3232.
49. Yu H & Rohan T 2000 Role of the insulin-like growth factor family in cancer development and progression. Journal of National Cancer Institute 92 1472-1489.
50. Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J & Diamandis EP 2001 Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 57 471-475.
51. Zapf J, Hauri C, Futo E, Hussain M, Rutishauser J, Maack CA & Froesch ER 1995 Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. Journal of Clinical Investigation 95 179-186.